Compare Incyte Corporation (INCY) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United States Oil ETF — how do they compare? Incyte Corporation trades at $113.14 (market cap $22.85B), while United States Oil ETF trades at $147.42 (market cap $1.90B). The key difference: Incyte Corporation is far larger — about 12× United States Oil ETF's market cap, and United States Oil ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and United States Oil ETF for 21 Days on average.
| INCY | USO | |
|---|---|---|
Market Cap | $22.85B | $1.90B |
Volume | 1,927,029 | 5,932,922 |
Sector | Health | — |
52-Week High | $129.93 | $161.86 |
52-Week Low | $83.80 | $66.17 |
Typical Hold Time | 33 Days | 21 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
USO is trading at $147.835, up 2.73% with a bullish technical signal from moving averages. The stock shows neutral oscillators but faces mixed oil market conditions with Middle East tensions and G-7 reserve releases creating volatility. Recent news highlights supply disruptions and geopolitical risks affecting crude prices.
The outlook remains cautious with geopolitical risks and supply uncertainties balancing against potential price support from production constraints. Investment opportunities exist if supply disruptions persist, but risks include regulatory pressures and volatile oil markets that could impact shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
